New Focus, New Offerings: A more dynamic and diverse proteomic service

Latest News from DC Biosciences: The team at DC Biosciences is excited about bringing new ideas and an improved focus as the world moves forward to an easier and more productive time. Our aim is to provide a more dynamic and diverse proteomic service enabling us to provide the best match for your unique research […]

What can proteomics contribute to COVID-19 research?

The COVID-19 pandemic is a global, public health crisis with far-reaching and long-term repercussions on the financial, physical, and psychological well-being of the population. As a consequence of the highly contagious nature of the disease, the virus has spread rapidly across the world. The disease is associated with severe pneumonia that often leads to acute […]

Jan Hewitt
When will you Click?

Click chemistry reactions are reactions between an alkyne-tagged molecule and an azide-tagged molecule which use copper as a catalyst. This was introduced by K. B. Sharpless in 2001 for which he was awarded half of the 2001 Nobel Prize in Chemistry. Sharpless developed these reactions in The Scripps Institute, California and has continued developing more […]

Shona Patton
ADAPTED Project meeting in Bonn – tackling Alzheimer’s Disease

Last week, my colleague Francesco Rao (DC Biosciences’ CSO) and I travelled to Bonn to participate in a progress meeting for ADAPTED (Alzheimer’s Disease Apolipoprotein Pathology for Treatment Elucidation and Development).     Bonn, the birthplace of Beethoven (though everyone’s favourite tortured pre-romantic composer spent most of his years in Vienna), is a relatively small city […]

Dr. Armel Nicolas
ADAPTED Project Press Release

New project to explore overlooked area of Alzheimer’s Disease research Alzheimer’s disease (AD) affects over 35 million people world-wide at present, these numbers are expected to grow substantially over the next few decades and there are currently no medicines which slow the progress of the disease. To boost the development of new medicines for AD, […]

Dr. Francesco Rao
Point of View